GDP dissociation inhibitor 2 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored GDI2P2 profile across patient tissues and cancer cell-line models. GDI2P2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GDI2P2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, GDI2P2 RNA expression shows 14,940 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where GDI2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GDI2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GDI2P2 survival associations across molecular data types. GDI2P2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GDI2P2 RNA expression–survival associations across cancer types. High GDI2P2 expression shows unfavorable associations in BLCA, KICH and MESO, but favorable associations in KIRC, LUSC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GDI2P2 RNA expression.
This table summarizes GDI2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GDI2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GDI2P2 shows higher tumor expression in COAD, LUSC, READ, BRCA, LUAD and KIRC. The COAD box plot shows higher GDI2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.878, t-test p < 0.001).
This table shows molecular features associated with GDI2P2 in patient tissues and cancer cell lines. In patient samples, GDI2P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
